TrialRMD open2025

Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study.

Joan T Merrill et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.